BCDA - BioCardia, Inc.
After hours:
Chart Events
Relative Strength Index (RSI)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.5200 |
| Open | 1.5300 |
| Bid | 1.7900 x 1200 |
| Ask | 1.9600 x 800 |
| Day's Range | 1.5300 - 1.9500 |
| 52 Week Range | 1.2300 - 2.6000 |
| Volume | |
| Avg. Volume | 28,271 |
| Market Cap | 37.608M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8000 |
| Earnings Date | Aug 08, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
Fair Value
Related Research
GlobeNewswireBioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study
SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next Data Safety Monitoring Board (DSMB) meeting for the CardiAMP Cell Therapy Trial for Heart Failure is scheduled to take place on July 12th. The Company expects the FDA’s response to its adaptive statistical analysis plan supplement early to mid-June and anticipates approva
Simply Wall St.BioCardia First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag
BioCardia ( NASDAQ:BCDA ) First Quarter 2023 Results Key Financial Results Revenue: US$64.0k (up 6.7% from 1Q 2022...
ZacksBioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -30.77% and 81.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
BioCardia Reports First Quarter 2023 Business Highlights and Financial Results
SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2023 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights
- GlobeNewswire
BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications
SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,642,377: titled, “ Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications”, with a patent term that will expire in 2039. The patent specification details methods f
- GlobeNewswire
BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023
SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three months ended March 31, 2023 and provide a corporate update by conference call on Wednesday, May 10, 2023 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for t
- GlobeNewswire
BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available
SUNNYVALE, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases has made available two presentations from the “Next Generation Cardiovascular Drug Development Summit on Executing Cell and Gene Therapy for Cardiac Regeneration” which took place this week on April 26-27, 2023 in Boston, MA. This inaugural summit was intended to delve into the understanding of gene
- GlobeNewswire
BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies
SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies. The United States Patent Office issued BioCardia Patent Number 11,716,859, entitled “Multi-Directional Steerable Catheter,” with a patent
Insider MonkeyBioCardia, Inc. (NASDAQ:BCDA) Q4 2022 Earnings Call Transcript
BioCardia, Inc. (NASDAQ:BCDA) Q4 2022 Earnings Call Transcript March 29, 2023 Operator: Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioCardia 2022 Yearend Conference Call. At this time, all participants are in a listen-only mode. I would now like to turn the conference over to of BioCardia Investor Relations. […]
- Simply Wall St.
We're Keeping An Eye On BioCardia's (NASDAQ:BCDA) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- GlobeNewswire
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2022 and filed its annual report on Form 10-K for the year ended December 31, 2022 with the Securities and Exchange Commission. The Company will also hold an update conference call at 4:30 PM ET today in which it will discuss business
- GlobeNewswire
BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023
SUNNYVALE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2022 and provide a corporate update conference call on Wednesday, March 29, 2023 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the c
BenzingaBioCardia Outlines Detailed Cell Therapy Data From Heart Failure Study
BioCardia Inc (NASDAQ: BCDA) presented detailed echocardiography data from the roll-in cohort of the Phase 3 CardiAMP Cell Therapy Heart Failure Trial. The echocardiography results from baseline through one and two years showed a more than doubling in the number of heart segments functioning normally and restoring function to 30% of previously non-functioning segments. This data expands upon what was previously presented at the Heart Failure Society of America annual meeting last fall. In this s
- GlobeNewswire
Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting
New Data from Roll-in Cohort of Trial Shows Progression of Patients from Baseline through One and Two Years Results Suggest CardiAMP Cell Therapy May Have Ability to Restore and Maintain Heart Function to Previously Non-Functioning Areas of the Heart Up to Two Years After Treatment SUNNYVALE, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces that det
- GlobeNewswire
BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
SUNNYVALE, Calif. and MULHOUSE, France, Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CellProthera, a private developer of cell-based therapies to repair ischemic tissues, today announce an amendment to their Clinical Research Supply and Support Agreement. The amendment extends the long-term partnership between both organizations. The agreement relates to Cell
- Simply Wall St.
Shareholders in BioCardia (NASDAQ:BCDA) are in the red if they invested five years ago
While it may not be enough for some shareholders, we think it is good to see the BioCardia, Inc. ( NASDAQ:BCDA ) share...
- GlobeNewswire
BioCardia Letter to Shareholders
SUNNYVALE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders: Dear Shareholders,BioCardia is now advancing four novel cell therapies, with three focused on heart disease, a leading cause of death and reduced quality of life globally. The Phase III trial of our lead therapy - CardiAMP® autologous cell th
- Simply Wall St.
Insider Buying: The BioCardia, Inc. (NASDAQ:BCDA) Independent Director Just Bought 14% More Shares
Potential BioCardia, Inc. ( NASDAQ:BCDA ) shareholders may wish to note that the Independent Director, Simon Stertzer...
- GlobeNewswire
BioCardia Announces $3.6 Million Private Placement of Common Stock
SUNNYVALE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a Securities Purchase and Registration Rights Agreement (the “Purchase Agreement”) relating to a private placement with certain new and existing qualified institutional buyers, institutional accredited investors and certain directors and office
Business WireBioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
SUNNYVALE, Calif., December 06, 2022--The FDA approves BioCardia's IND application to start a Phase I/II clinical trial of its NK1R+ allogeneic mesenchymal cell therapy for heart failure.
ZacksBioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results
SUNNYVALE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2022 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2022 with the United States Securities and Exchange Commission (SEC). The Company will also hold an update conference call today at 4:30 PM ET. F
ZacksBioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know
BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire
BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022
SUNNYVALE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and nine months ended September 30, 2022 and provide a corporate update by conference call on Wednesday, November 9, 2022 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session. Participants
BenzingaBioCardia's Heart Failure Cell Therapy Shows 100% Survival At Two Years
BioCardia Inc (NASDAQ: BCDA) announced data from its CardiAMP Cell Therapy for Heart Failure pivotal trial. "The two-year outcomes for patients with heart failure receiving the investigational CardiAMP Cell Therapy in the roll-in cohort showed clinical improvement with 100% survival over two years. These outcomes surpassed our expectations in terms of patient benefit across prespecified primary and secondary endpoints," said Peter Altman, BioCardia's President & CEO. "While this smaller cohort i